Health Catalyst Acquires Oncology-Focused Health Technology Company Carevive
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Citi Reiterates Buy Rating on Health Catalyst Inc. (HCAT)
June 6, 2024 10:32 AM EDTCiti analyst Daniel Grosslight reiterated a Buy rating and $9.00 price target on Health Catalyst Inc. (NASDAQ: HCAT).
The analyst comments "We caught up with HCAT after the company announced its acquisition of Carevive, an oncology-focused health tech company (LINK). Carevive serves both Oncology Practices and Life... More
